A randomized study comparing the pharmacokinetics and safety outcomes of subcutaneous and intramuscular peginterferon beta-1a in Black/African American and White participants
Latest Information Update: 01 Jun 2022
At a glance
- Drugs Peginterferon beta-1a (Primary) ; Peginterferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
Most Recent Events
- 01 Jun 2022 New trial record
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022